Jääskeläinen J, Levo A, Voutilainen R, Partanen J
Department of Pediatrics, Kuopio University Hospital, Finland.
J Clin Endocrinol Metab. 1997 Oct;82(10):3293-7. doi: 10.1210/jcem.82.10.4271.
We report a population-wide analysis of all patients with 21-hydroxylase deficiency (21-OHD) found in Finland, a country with a genetically well defined population, in which the effects of other genetic and environmental factors on the phenotype can be expected to be low. In total, 120 patients were identified, and their clinical status was evaluated. Blood samples for CYP21 genotype determination could be obtained from 78 (65%) patients, and their phenotypes were compared with their genotypes. In general, the severity of gene defects correlated well with clinical expression. All patients carrying mutations with the most drastic effects on enzymatic activity had the salt-wasting form of 21-OHD. The I2 splice mutation, which in some reports has been connected with clinical variation, was constantly associated with severe mineralocorticoid deficiency. However, patients with I172N as the determining mutation expressed a wide spectrum of phenotypes; the variation could not be attributed to additional mutations. Although genetically affected males with the nonclassical form had not been clinically diagnosed, our study suggests that nonclassical 21-OHD is substantially more rare in Finland than elsewhere, as indicated by both clinical evaluation and mutational screening.
我们报告了对芬兰所有21-羟化酶缺乏症(21-OHD)患者进行的一项全人群分析。芬兰是一个基因特征明确的国家,预计其他遗传和环境因素对表型的影响较小。总共识别出120例患者,并对他们的临床状况进行了评估。从78例(65%)患者中获取了用于CYP21基因分型测定的血样,并将他们的表型与其基因型进行了比较。总体而言,基因缺陷的严重程度与临床表现密切相关。所有携带对酶活性影响最严重突变的患者均为失盐型21-OHD。I2剪接突变在一些报告中与临床变异有关,它一直与严重的盐皮质激素缺乏相关。然而,以I172N作为决定性突变的患者表现出广泛的表型;这种变异不能归因于其他突变。尽管未对携带非经典型基因的男性进行临床诊断,但我们的研究表明,无论是通过临床评估还是突变筛查,非经典型21-OHD在芬兰都比其他地方更为罕见。